• Susan G. Komen® Honored for $20 Million in Research Investments to Dana-Farber Cancer Institute

    World’s Largest Breast Cancer Organization, Dana-Farber Mark Decades of Partnership

    DALLAS – Sept. 25, 2013 – Susan G. Komen and the Dana-Farber Cancer Institute marked a significant milestone today with a ceremony honoring Komen for funding more than $20 million in breast cancer research during the past two decades at Dana-Farber, one of the nation’s oldest and best-known cancer research institutions.

    Komen founder and Chair, Global Strategy Nancy G. Brinker, and Komen President and CEO Judith A. Salerno, M.D., M.S., were recognized at an event that featured remarks from the Institute's top researchers about the advancements in breast cancer research generated thanks in part to Komen’s long partnership.

    Komen is the largest nonprofit funder of breast cancer research in the U.S., with more than $790 million invested since Komen was founded in 1982.

    Komen first funded Dana-Farber research almost 20 years ago, with a $100,000 grant in 1995 to Dana-Farber researcher Myles Brown, M.D., for his study on “Transcriptional Regulation of Estrogen Receptor in Breast Cancer.” Currently, Komen is funding more than $13.3 million in active research grants at the Boston institution.

    “We cannot think of a more worthy investment in the fight against breast cancer than to the researchers at Dana-Farber,” said Nancy Brinker. “This leading cancer institute is not only dedicated to new therapy and outcomes for women of all ages and cultures, but also the development of young scientific talent which is a central part of this institution.”

    The Komen and Dana-Farber relationship goes beyond research funding.  Dr. Eric Winer, Dana-Farber’s Chief of Women’s Cancers and Director of the breast oncology program at the Susan F. Smith Center for Women’s Cancers, has served as Komen’s Chief Scientific Advisor since 2007 and is the co-chair of its Scientific Advisory Board. Dr. Brown serves as a member of Komen's Scientific Advisory Board. Additionally, five clinicians and researchers from Dana-Farber and Harvard Medical School serve as Komen Scholars, advising the organization on research funding through Komen’s scientific peer review process.

    Salerno, who joined Komen as president and CEO Sept. 9, received her M.D. and Masters of Science in Public Health from Harvard Medical School. The Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School.

    “I know from personal experience the dedication of the scientists and clinicians here at Dana-Farber, and the tremendous strides that have been made here,” Salerno said. “We’re honored to work in partnership with one of the world’s great institutions in our mission to end breast cancer.”

    "We are extremely grateful to Susan G. Komen for its steadfast commitment to funding and support of breast cancer research at Dana-Farber,” said Dr. Winer. "Komen’s investment in research has had a measurable impact on the lives of breast cancer patients, and it will continue to save lives as discoveries made by Komen-funded scientists today will result in better and more effective treatments in the years ahead.”

    Grants to Dana Farber Cancer Institute – FY13:
    Systematic Characterization of Resistance to HER2-Targeted Breast Cancer Therapy
    Investigator(s): Susan Moody, M.D., Ph.D.

    Stalled Fork Repair Defect Predisposes BRCA1 Mutation Carriers to Breast Cancer
    Investigator(s): Shailja Pathania, Ph.D.

    Overcoming Drug Resistance in Tumors with Autophagy-Promoting Amplifications
    Investigator(s): Andrea Richardson, M.D., Ph.D.

    Pharmacogenetics of Platinum Response in Breast Cancer (No Abstract)
    Investigator(s): Judy Garber, M.D., M.P.H.

    The Role of EGFR Signaling in Resistance to HER2-directed Therapy
    Investigator(s): Ian Krop, M.D., Ph.D.

    Cellular and Organ Based Outcomes of Defective, BRCA1-Driven Mutagenesis Control
    Investigator(s): David Livingston, M.D.

    Breast Cancer in Young Women
    Investigator(s): Anne Partridge, M.D., M.P.H.

    Clinical Trials for HER2+ Breast Cancer (No Abstract)  
    Investigator(s): Eric Winer, M.D.

    Grants to Brigham and Women’s Hospital – FY13:
    Breast Cancer Risk in Chronic Users of Phthalate-Containing Medications
    Investigator(s): Thomas Ahern, Ph.D.

    Environmental Exposures, Early Proliferative Changes and Breast Cancer Risk
    Investigator(s): Rulla Tamimi, Sc.D.; Francine Laden, Sc.D.

    Using Breast Tissue Expression Patterns to Inform Our Understanding of Breast Cancer Risk Factors
    Investigator(s): Susan Hankinson, Sc.D.

    Grants to Harvard Medical School – FY13:
    Analysis of the Integration of Cell-Cell Adhesion & Yap Networks Regulating Tumor Growth & Invasion
    Investigator(s):Joan Brugge, Ph.D.